A preclinical-stage biotechnology company developing induced mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases, with lead programs ERNA-101 for ovarian cancer and ERNA-201 for rheumatoid arthritis.
Cambridge, MA, United States~5 employeesFounded Jan 2018Website